Academic Commons

Articles

Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis

Ricci, Susanna; Grandgirard, Denis; Wenzel, Michael; Braccini, Tiziana; Salvatore, Paola; Oggioni, Marco; Leib, Stephen; Koedel, Uwe

Approximately 7% of survivors from meningococcal meningitis (MM) suffer from neurological sequelae due to brain damage in the course of meningitis. The present study focuses on the role of matrix metalloproteinases (MMPs) in a novel mouse model of MM-induced brain damage. The model is based on intracisternal infection of BALB/c mice with a serogroup C Neisseria meningitidis strain. Mice were infected with meningococci and randomised for treatment with the MMP inhibitor batimastat (BB-94) or vehicle. Animal survival, brain injury and host-response biomarkers were assessed 48 h after meningococcal challenge. Mice that received BB-94 presented significantly diminished MMP-9 levels (p < 0.01), intracerebral bleeding (p < 0.01), and blood-brain barrier (BBB) breakdown (p < 0.05) in comparison with untreated animals. In mice suffering from MM, the amount of MMP-9 measured by zymography significantly correlated with both intracerebral haemorrhage (p < 0.01) and BBB disruption (p < 0.05). MMPs significantly contribute to brain damage associated with experimental MM. Inhibition of MMPs reduces intracranial complications in mice suffering from MM, representing a potential adjuvant strategy in MM post-infection sequelae.

Files

  • thumnail for sword-351178355464843344154.zip sword-351178355464843344154.zip binary/octet-stream 590 KB Download File
  • thumnail for s12879-014-0726-6-S1.docx s12879-014-0726-6-S1.docx binary/octet-stream 27.5 KB Download File

Also Published In

Title
BMC Infectious Diseases
DOI
https://doi.org/10.1186/s12879-014-0726-6

More About This Work

Academic Units
Biological Sciences
Publisher
BioMed Central
Published Here
January 19, 2015